Sign inJoin waitlistJoin the waitlist

Sarmad Sadeghi

, Associate Professor of Clinical Medicine · University of Southern California/Los Angeles General Medical Center

Credentials: · · · ·

History

University of Southern California/Los Angeles General Medical Center
Present

Cleveland Clinic Foundation
2006–2008
University of Texas Medical School at Houston - Ruiz Dept of Ophthalmology & Visual Science
2003–2006
Baylor College of Medicine
2000–2003
Cleveland Clinic Foundation
1997–2000
University of Texas Health Science Center at Houston
1996–1997
Doctor of Medicine
1992–1996

Research

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)
Case report · Annals of the Rheumatic Diseases · 2002 · 102 citations
Comparative effectiveness of screening strategies for colorectal cancer
Cancer · 2017 · Last of 4 authors · 44 citations
Comparative effectiveness of screening strategies for Lynch syndrome
Journal of the National Cancer Institute · 2015 · 43 citations

AB
Afsaneh Barzi
17 papers · 5 as a resident
David Quinn
14 papers
Inderbir Gill
9 papers
Parkash Gill
8 papers
TD
Tanya Dorff
8 papers
Primo Lara
5 papers
Sia Daneshmand
5 papers
AJ
Alexandra Jackovich
3 papers · 2 as a resident
EK
Eric Klein
3 papers
Giovanni Cacciamani
3 papers
LB
Leslie Ballas
3 papers
Monish Aron
3 papers

Grants

Synergistic Immune Response After EphrinB2 Inhibition & PD-1 Antibody Therapy in Urothelial Carcinoma.
National Cancer Institute · R01
Contact PI · $1.4M · University of Southern California
2025–2030

Clinical trials

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Principal investigator · Recruiting · Phase 2, Phase 3
Vasgene Therapeutics, Inc
2025–2034
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2021–2030
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
Principal investigator · Unknown · Phase 2
Vasgene Therapeutics, Inc
2020–2025
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
Principal investigator · Active not recruiting · Phase 2
University of Southern California
2017–2027